Biopeutics Co., Ltd.

Innovate to Improve Quality of Life

Home

About Us

Products

EUBEATLIN

DES

Contact Us

Biopeutics Co. Ltd. is a medical therapeutic company that has existing registered pharmaceutical products & a pipeline of new and emerging products, in particular for the cardiovascular markets. Biopeutics has a main focus on new indication development for pre-existing tested and regulatory approved drugs, so as to fasttrack to market and to generate revenue. Biopeutics also has an interest in the development of medical devices, in particular for new generation of vascular stenting. The Biopeutics team is working on new indications for existing drugs and preparing to bring these expeditiously to the approval stage by the regulatory authorities .  

News and Events

U.S. Food and Drug Administration(FDA):
September 9th 2022

Pre-IND Brief Package Type C

December 9th 2022
Pre-IND Teleconference

December 22th 2022
FDA meeting minutes

European Medicines Agency (EMA):
Submission of European clinical trial review documents to EMA on March 13, 2023 March 15, 2023 EMA has accepted applications for European clinical trials April 14, 2023 EMA has replied as following: Following the SAWP first report discussion of your case EMA/SA/0000129062 (Follow up Scientific Advice - Human), the SAWP has decided that there is no need for a discussion meeting (40-day procedure). Therefore you should expect to receive the final advice letter by the end of the week following the next CHMP plenary.
We are expecting the written letter from 04/26-05/05.



Copyright © 2023 Biopeutics Co. Ltd. All rights reserved.